-
公开(公告)号:US20080249180A1
公开(公告)日:2008-10-09
申请号:US12044002
申请日:2008-03-07
申请人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
发明人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
IPC分类号: A61K31/165 , C07C233/01
CPC分类号: C07C233/29 , C07C233/15 , C07C233/32 , C07C233/88 , C07C2601/02 , C07C2601/08 , C07D211/16 , C07D211/46 , C07D213/40 , C07D213/75 , C07D295/185 , C07D309/14
摘要: The present invention relates to compounds of formula I wherein Ar1, Ar2, R, R1, R2, R3 and n are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved like sleep disorders.
摘要翻译: 本发明涉及式I化合物,其中Ar 1,Ar 2,R 1,R 1,R 2, >,R 3和n如本文所定义,或其药学上合适的酸加成盐,光学纯对映异构体,外消旋体或非对映体混合物。 式I化合物是食欲素受体拮抗剂,可用于治疗其中食欲素途径如睡眠障碍的疾病。
-
公开(公告)号:US20080221166A1
公开(公告)日:2008-09-11
申请号:US12037975
申请日:2008-02-27
申请人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
发明人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
IPC分类号: A61K31/4427 , C07C233/00 , A61K31/165 , C07D211/04 , A61K31/44
CPC分类号: C07D213/36 , A61K9/2018 , A61K9/4858 , C07C237/20 , C07C2601/02 , C07C2601/04
摘要: The present invention relates to compounds of formula I wherein Ar1, Ar2, Ar3, n, and R1 to R8 are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved, like sleep disorders.
摘要翻译: 本发明涉及式I化合物,其中Ar 1,Ar 2,Ar 3,n和R 1, 其中R 8和R 8如本文所定义,并且与药学上合适的酸加成盐,光学纯对映异构体,外消旋物或非对映体混合物。 这些化合物是食欲肽受体拮抗剂,并且可用于治疗涉及食欲素途径的疾病,例如睡眠障碍。
-
43.
公开(公告)号:US20070082936A1
公开(公告)日:2007-04-12
申请号:US11543178
申请日:2006-10-04
申请人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
发明人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
IPC分类号: A61K31/42 , C07D413/02
CPC分类号: C07D413/14
摘要: The present invention is concerned with aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives of formula I wherein R1, R2, R3, R4, and R5 are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. The invention also relates to methods for preparing such compounds. This class of compounds has a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease. Thus, the invention also is concerned with pharmaceutical compositions containing compounds of formula I or their pharmaceutically acceptable acid addition salts and methods for the treatment of GABA A α5 mediated diseases, including Alzheimer's disease.
摘要翻译: 本发明涉及式I的芳基 - 异恶唑-4-羰基 - 吲哚 - 羧酸酰胺衍生物,其中R 1,R 2,R 3, R 4,R 4和R 5如说明书和权利要求书及其药学上可接受的酸加成盐所定义。 本发明还涉及制备这些化合物的方法。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,可能作为认知增强剂或治疗阿尔茨海默病等认知障碍。 因此,本发明还涉及含有式I化合物或其药学上可接受的酸加成盐的药物组合物和用于治疗包括阿尔茨海默氏病在内的GABA Aα5介导的疾病的方法。
-
公开(公告)号:US20070066668A1
公开(公告)日:2007-03-22
申请号:US11520394
申请日:2006-09-13
申请人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
发明人: Bernd Buettelmann , Bo Han , Henner Knust , Matthias Nettekoven , Andrew Thomas
IPC分类号: A61K31/42 , C07D413/02
CPC分类号: C07D413/14 , C07D413/06 , C07D451/06
摘要: The present invention is concerned with aryl-isoxazole-4-carbonyl-pyrrole-2-carboxylic acid amide derivatives of formula wherein R1, R2, R3, R4, and R5, and m are as defined herein and with their pharmaceutically acceptable acid addition salts. This class of compounds have high affinity and selectivity for GABA A α5 receptor binding sites and therefore may be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
摘要翻译: 本发明涉及下式的芳基 - 异恶唑-4-羰基 - 吡咯-2-羧酸酰胺衍生物其中R 1,R 2,R 3, R 4,R 4和R 5,m如本文所定义,并与其药学上可接受的酸加成盐反应。 这类化合物对GABA Aα5受体结合位点具有高亲和力和选择性,因此可用作认知增强剂或治疗认知障碍如阿尔茨海默病。
-
公开(公告)号:US08207220B2
公开(公告)日:2012-06-26
申请号:US12958440
申请日:2010-12-02
IPC分类号: A61K31/38
CPC分类号: C07D413/12 , C07D403/12 , C07D413/14 , C07D417/12
摘要: The present invention is concerned with novel sulfonamides of formula I wherein R1, R2, Ar, Hetaryl, m and n are as described in the description and claims. The compounds are orexin receptor antagonists, useful in the treatment of disorders, in which orexin pathways are involved.
摘要翻译: 本发明涉及式I的新型磺酰胺,其中R 1,R 2,Ar,杂芳基,m和n如说明书和权利要求中所述。 这些化合物是食欲素受体拮抗剂,可用于治疗食欲素途径参与的病症。
-
公开(公告)号:US07829563B2
公开(公告)日:2010-11-09
申请号:US12037975
申请日:2008-02-27
申请人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
发明人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
IPC分类号: A61K31/50 , A61K31/501 , A61K31/497 , A01N43/54 , C07D239/42 , C07D401/04 , A01N43/40 , A61K31/435 , A01N43/78 , A61K31/425 , A01N43/50 , A61K31/415 , A01N43/56 , A01N43/08 , A61K31/34 , C07D279/00 , C07D285/00 , C07D401/00 , C07D421/00 , C07D419/00 , C07D277/04 , C07D277/08 , C07D409/00 , C07D335/00 , C07D333/02 , C07D321/00 , C07D307/00 , C07D317/00 , C07D323/02
CPC分类号: C07D213/36 , A61K9/2018 , A61K9/4858 , C07C237/20 , C07C2601/02 , C07C2601/04
摘要: The present invention relates to compounds of formula I wherein Ar1, Ar2, Ar3, n, and R1 to R8 are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved, like sleep disorders.
摘要翻译: 本发明涉及式I化合物,其中Ar1,Ar2,Ar3,n和R1至R8如本文所定义,以及其药学上合适的酸加成盐,光学纯对映异构体,外消旋体或非对映体混合物。 这些化合物是食欲肽受体拮抗剂,并且可用于治疗涉及食欲素途径的疾病,例如睡眠障碍。
-
公开(公告)号:US20100029664A1
公开(公告)日:2010-02-04
申请号:US12506302
申请日:2009-07-21
IPC分类号: A61K31/498 , C07D413/12 , A61K31/423 , C07D417/12 , A61K31/428 , C07D413/14 , C07D417/14 , C07D403/12
CPC分类号: C07D413/12 , C07D403/12 , C07D413/14 , C07D417/12
摘要: The present invention is concerned with novel sulfonamides of formula I wherein R1, R2, Ar, Hetaryl, m and n are as described in the description and claims. The compounds are orexin receptor antagonists, useful in the treatment of disorders, in which orexin pathways are involved.
摘要翻译: 本发明涉及式I的新型磺酰胺,其中R 1,R 2,Ar,杂芳基,m和n如说明书和权利要求中所述。 这些化合物是食欲素受体拮抗剂,可用于治疗食欲素途径参与的病症。
-
公开(公告)号:US20090163485A1
公开(公告)日:2009-06-25
申请号:US12334559
申请日:2008-12-15
IPC分类号: A61K31/5365 , C07D263/54 , A61K31/421 , C07D241/36 , A61K31/498 , C07D417/02 , A61K31/428 , C07D221/00 , A61K31/4245 , A61P25/00 , A61K31/501 , C07D403/02 , A61K31/505 , C07D239/24 , C07D271/06 , A61K31/454 , C07D215/38 , A61K31/4709 , C07D239/72 , A61K31/517 , C07D265/12
CPC分类号: C07D413/12 , C07D401/12 , C07D409/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D498/04
摘要: The present invention relates to compounds of formula wherein Ar, Het, R1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.
摘要翻译: 本发明涉及下式的化合物其中Ar,Het,R 1和n如本文所定义,并且与药学上合适的酸加成盐,光学纯对映异构体,外消旋物或非对映体混合物相关。 式I化合物是食欲蛋白受体拮抗剂,可用于治疗睡眠呼吸暂停,发作性睡病,失眠,睡眠不正,夜间综合征,昼夜节律障碍和与神经疾病相关的睡眠障碍。
-
公开(公告)号:US07501541B2
公开(公告)日:2009-03-10
申请号:US12044002
申请日:2008-03-07
申请人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
发明人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
IPC分类号: C07C233/05 , A61K31/65
CPC分类号: C07C233/29 , C07C233/15 , C07C233/32 , C07C233/88 , C07C2601/02 , C07C2601/08 , C07D211/16 , C07D211/46 , C07D213/40 , C07D213/75 , C07D295/185 , C07D309/14
摘要: The present invention relates to compounds of formula I wherein Ar1, Ar2, R, R1, R2, R3 and n are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved like sleep disorders.
摘要翻译: 本发明涉及式I化合物,其中Ar1,Ar2,R,R1,R2,R3和n如本文所定义,或其药学上合适的酸加成盐,光学纯对映异构体,外消旋物或非对映体混合物。 式I化合物是食欲素受体拮抗剂,可用于治疗其中食欲素途径如睡眠障碍的疾病。
-
公开(公告)号:US20090036422A1
公开(公告)日:2009-02-05
申请号:US12178688
申请日:2008-07-24
IPC分类号: A61K31/397 , A61K31/165 , A61K31/52 , A61K31/437 , C07C233/88 , C07D471/04 , C07D487/04 , C07D491/107
CPC分类号: C07D405/12 , C07C233/29 , C07C235/38 , C07C235/80 , C07C237/20 , C07C237/22 , C07C251/48 , C07C255/58 , C07C255/60 , C07C271/22 , C07D205/04 , C07D207/12 , C07D209/44 , C07D211/46 , C07D213/56 , C07D231/56 , C07D235/06 , C07D235/08 , C07D235/10 , C07D235/16 , C07D235/26 , C07D277/62 , C07D305/02 , C07D305/08 , C07D307/14 , C07D307/52 , C07D307/79 , C07D317/28 , C07D317/46 , C07D317/66 , C07D319/20 , C07D333/24 , C07D471/04 , C07D487/04 , C07D491/107
摘要: The present invention relates to compounds of formula wherein Ar, R1, R2, R3, R4, R5, n, o, and p are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula I can be used for the treatment of sleep disorders, such as sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.
摘要翻译: 本发明涉及下式的化合物其中Ar,R 1,R 2,R 3,R 4,R 5,n,o和p如本文所定义,或其药学上合适的酸加成盐,光学纯对映异构体,外消旋体或非对映体混合物。 式I化合物可用于治疗睡眠呼吸暂停,发作性睡病,失眠,睡眠不正常,时差综合征,昼夜节律障碍或与神经疾病相关的睡眠障碍的睡眠障碍。
-
-
-
-
-
-
-
-
-